Literature DB >> 21461570

Troglitazone induces apoptosis in gastric cancer cells through the NAG-1 pathway.

Chunhui Wang1, Jing Wang, Ping Bai.   

Abstract

The non-steroidal anti-inflammatory drug-activated gene (NAG-1) is a newly identified member of the transforming growth factor (TGF)-β superfamily and plays significant roles in regulating proliferation and pro-apoptotic activities. In the present study, we studied the regulation of NAG-1 by troglitazone in the cultured gastric cancer cell line BGC-823. MTT and TUNEL assays demonstrated that troglitazone potentially inhibits the proliferation of the gastric cancer cell line and induces apoptosis in vitro in a dose- and time-dependent manner. Troglitazone induced concentration-dependent NAG-1 expression in the BGC-823 cells, as assessed using immunocytochemistry. Furthermore, troglitazone increased Egr-1 protein levels in a concentration-dependent manner. In conclusion, the present study suggests that troglitazone markedly impedes proliferation and pro-apoptotic activities in BGC-823 cells, and the mechanism may partly be through the Egr-1 pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21461570     DOI: 10.3892/mmr.2010.381

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.

Authors:  Aparna Natarajan; Balaji Ramachandran; Gopal Gopisetty; Subramani Jayavelu; Shirley Sundersingh; Thangarajan Rajkumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-05       Impact factor: 3.000

2.  Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.

Authors:  Jinjun Ye; Li Yin; Peng Xie; Jianfeng Wu; Jian Huang; Guoren Zhou; Hanzi Xu; Emei Lu; Xia He
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

Review 3.  Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Maria Tsironi
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-06

4.  Identification of putative drugs for gastric adenocarcinoma utilizing differentially expressed genes and connectivity map.

Authors:  Zu-Xuan Chen; Xiao-Ping Zou; Huang-Qun Yan; Rui Zhang; Jin-Shu Pang; Xin-Gan Qin; Rong-Quan He; Jie Ma; Zhen-Bo Feng; Gang Chen; Ting-Qing Gan
Journal:  Mol Med Rep       Date:  2018-12-13       Impact factor: 2.952

5.  Troglitazone and tumor inhibition: an evolving concept in the management of systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Radiat Oncol J       Date:  2012-12-31

6.  Variations in NAG-1 expression of human gastric carcinoma and normal gastric tissues.

Authors:  Gongli Yang; Qinhua Tan; Yongmei Xie; Bin Wei; Zhixin Chen; Chengwei Tang; Shengbao Li; Chunhui Wang
Journal:  Exp Ther Med       Date:  2013-10-24       Impact factor: 2.447

7.  Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2016-01-11

8.  CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

Authors:  Mengjiao Han; Dongjun Dai; Neelum Aziz Yousafzai; Faliang Wang; Hanying Wang; Qiying Zhou; Haiqi Lu; Wenxia Xu; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Oncotarget       Date:  2017-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.